We hypothesized that elevated NQO1 would confer chemoresistance in PDAC and predict poor patient outcome.<h4>Methods</h4>NQO1 tumor levels and germline C609T SNP status were assessed in archival samples from the European Study Group for Pancreatic Cancer (ESPAC) trials. The gene discussed is NQO1; the disease is familial pancreatic carcinoma.